iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Ipca to acquire 33.38% stake in Unichem Laboratories for Rs 1034.06 crore

25 Apr 2023 , 12:00 PM

Ipca will acquire 33.38% stake in Unichem Laboratories for Rs 1,034.06 crore. 

The purchase of 2,35,01,440 fully paid-up equity shares worth Rs 21 each, or about 33.38% of the paid-up share capital of Unichem Laboratories, a listed entity, from one of its promoter shareholders for a price of Rs 440 per equity share, amounting to R 1034.06 crore, was approved by the board, according to a filing with the exchange by Ipca.

 Competition Commission of India must approve this proposed transaction.

According to the company, 'The board of directors also approved making an open offer to the public shareholders of Unichem Laboratories to acquire from them up to 26% of the fully diluted outstanding equity share capital of the said company at Rs 440/- per share totaling Rs 805.44 crore.'

Ipca's shares concluded Monday's trading session 1.9% lower than the previous day's closing price of Rs841.3 a share, at Rs825.5. The stock has dropped over 17% over the past year, and over 12% over the past six months.

Amrut Mody, a pioneer in the Indian pharmaceuticals industry, launched Unichem in 1944 as a solo proprietorship corporation. Unichem is a global, integrated, specialty pharmaceutical company. It produces and sells a wide variety of pharmaceutical formulations both as branded generics and generics in a number of international marketplaces, with the United States of America and Europe serving as the two largest markets.

Manufacturing facilities for Unichem formulations are located in Goa, Ghaziabad, and Baddi in Himachal Pradesh. The manufacturing facilities for Active Pharmaceutical Ingredients (API) are located in Roha, Kolhapur, and Pithampur, respectively, in Maharashtra.

For feedback and suggestions, write to us at editorial@iifl.com

explored-media

Related Tags

  • CCI
  • Ipca
  • Unichem Labs
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

closeIcon

Get better recommendations & make better investments

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp